Core Viewpoint - The company has completed an additional capital injection of HKD 30 million into its wholly-owned subsidiary TGM, bringing TGM's total paid-up capital to HKD 150 million, which is expected to enhance its business expansion and market competitiveness [1][2] Group 1: Capital Injection Details - The total capital injection into TGM has reached HKD 83 million prior to this latest round, with the recent injection of HKD 30 million aimed at strengthening TGM's capital base [1] - Following this capital increase, the company's ownership percentage in TGM remains unchanged [1] Group 2: TGM's Performance and Future Prospects - TGM has reported impressive performance with revenues of approximately HKD 44.9 million for the six months ending September 30, 2025, marking a nearly 400% increase compared to the same period last year [1] - The capital enhancement is expected to significantly improve TGM's risk resilience and business capacity, facilitating the expansion of its IPO underwriting and margin financing services [2] - The board believes that this capital injection will lay a solid foundation for TGM's future growth, aligning with the best interests of the company and its shareholders [2]
捷利交易宝(08017)完成对TGM进一步增资3000万港元